De variolarum et morbillorum natura accuratione

originaal asub Göttingeni Ülikooli raamatukogus. Avaldatud valdaja loal

Pottery production and trade in the Banda zone, Indonesia: the Kei tradition in its spatial and historical context

This paper provides the first comprehensive description of pottery production in the Kei islands of eastern Indonesia, based on field data collected mainly in 1981 and on Museum collections in the UK and The Netherlands. The account is situated in what we know of the dynamics of trading systems that existed in the Moluccan islands between 1500 and 2000. Kei pottery is widely thought to be the successor of a tradition established in the Banda islands that was extinguished with the 1621 Dutch massacre of Bandanese, but re-established at several sites in the Kei islands by Bandanese migrants after this date. These claims are critically examined using ethnographic and archaeological data, and an attempt made to compare the production and trading patterns of pottery in the ‘Banda zone’ before and after 1621

PHREND®—A Real-World Data-Driven Tool Supporting Clinical Decisions to Optimize Treatment in Relapsing-Remitting Multiple Sclerosis

BackgroundWith increasing availability of disease-modifying therapies (DMTs), treatment decisions in relapsing-remitting multiple sclerosis (RRMS) have become complex. Data-driven algorithms based on real-world outcomes may help clinicians optimize control of disease activity in routine praxis.ObjectivesWe previously introduced the PHREND® (Predictive-Healthcare-with-Real-World-Evidence-for-Neurological-Disorders) algorithm based on data from 2018 and now follow up on its robustness and utility to predict freedom of relapse and 3-months confirmed disability progression (3mCDP) during 1.5 years of clinical practice.MethodsThe impact of quarterly data updates on model robustness was investigated based on the model's C-index and credible intervals for coefficients. Model predictions were compared with results from randomized clinical trials (RCTs). Clinical relevance was evaluated by comparing outcomes of patients for whom model recommendations were followed with those choosing other treatments.ResultsModel robustness improved with the addition of 1.5 years of data. Comparison with RCTs revealed differences &amp;lt;10% of the model-based predictions in almost all trials. Treatment with the highest-ranked (by PHREND®) or the first-or-second-highest ranked DMT led to significantly fewer relapses (p &amp;lt; 0.001 and p &amp;lt; 0.001, respectively) and 3mCDP events (p = 0.007 and p = 0.035, respectively) compared to non-recommended DMTs.ConclusionThese results further support usefulness of PHREND® in a shared treatment-decision process between physicians and patients.</jats:sec

The reptilian vestibular and cerebellar gray with fiber connections

No Abstract.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/49912/1/900650110_ftp.pd

Table_1_PHREND®—A Real-World Data-Driven Tool Supporting Clinical Decisions to Optimize Treatment in Relapsing-Remitting Multiple Sclerosis.docx

BackgroundWith increasing availability of disease-modifying therapies (DMTs), treatment decisions in relapsing-remitting multiple sclerosis (RRMS) have become complex. Data-driven algorithms based on real-world outcomes may help clinicians optimize control of disease activity in routine praxis.ObjectivesWe previously introduced the PHREND® (Predictive-Healthcare-with-Real-World-Evidence-for-Neurological-Disorders) algorithm based on data from 2018 and now follow up on its robustness and utility to predict freedom of relapse and 3-months confirmed disability progression (3mCDP) during 1.5 years of clinical practice.MethodsThe impact of quarterly data updates on model robustness was investigated based on the model's C-index and credible intervals for coefficients. Model predictions were compared with results from randomized clinical trials (RCTs). Clinical relevance was evaluated by comparing outcomes of patients for whom model recommendations were followed with those choosing other treatments.ResultsModel robustness improved with the addition of 1.5 years of data. Comparison with RCTs revealed differences ®) or the first-or-second-highest ranked DMT led to significantly fewer relapses (p ConclusionThese results further support usefulness of PHREND® in a shared treatment-decision process between physicians and patients.</p